Eli Lilly and Company (NYSE: LLY) revealed a significant $3 billion investment to construct a brand-new, cutting-edge manufacturing plant in Katwijk, the Netherlands. The facility, which is part of the esteemed Leiden Bio Science Park, is expected to greatly increase the company’s capacity to produce its expanding line of oral solid medications globally.
With an emphasis on oral therapies for immunology, oncology, neuroscience, and cardiometabolic health, the new facility will serve as a pillar of Lilly’s supply chain. The company’s first-in-class oral, small-molecule GLP-1 receptor agonist, orforglipron, will also be manufactured there. By the end of this year, Lilly plans to submit orforglipron for the treatment of obesity to international regulatory bodies.
With extensive investments already underway in the U.S., our planned expansion in Europe
David A. Ricks
further strengthens our ability to deliver medicines to patients worldwide. Localized manufacturing ensures we can quickly respond to meet regional demand and accelerate distribution within Europe
The province of South Holland will gain 500 new, well-paying jobs thanks to this investment, which will need highly qualified lab technicians, engineers, and scientists. The construction phase is scheduled to start next year, subject to final government permits and local approvals, and is anticipated to generate an additional 1,500 jobs.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
The state-of-the-art manufacturing technologies at the Katwijk plant will include:
- Material flow and dock-to-dock automation.
- Paperless production methods.
- PAT stands for advanced process analytical technology.
- Spray-dried dispersion, a key technique for ensuring oral medicines are effectively absorbed.
Last Modified:
